Latest research publications, press coverage, and institutional announcements from the Semenov Lab at MGH and Harvard Medical School.
A study of 39,258 immune checkpoint inhibitor recipients across two independent cohorts found that systemic glucocorticoid use was associated with significantly shorter overall survival — with the most pronounced association when steroids were given within one month of immunotherapy initiation, at doses above 60 mg/day, or for more than seven days.
Wan G*, Nguyen N*, Lu C, … Kwatra SG, Semenov YR. JAMA Network Open. 2026. DOI: 10.1001/jamanetworkopen.2026.14323
"Their use during immunotherapy should be treated as a major clinical decision. Our study helps with that decision by identifying specific timing, dose, and duration patterns most strongly associated with poorer survival outcomes." — Eugene Semenov, MD, MA, FAAD
